Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
Where this comes from
- Record sourced from PubMed, PMID 26565677.
- Also identified by DOI 10.1146/annurev-med-120214-013614.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.